top of page
Frequently Asked Questions
What is psilocybin?
Psilocybin is a naturally occurring compound found in certain species of mushrooms, sometimes called "magic mushrooms." When consumed, psilocybin is converted in the body into its active form, psilocin, which affects the brain by acting on serotonin receptors — chemical messengers involved in mood, perception, and thinking. At therapeutic doses administered in a supervised clinical setting, psilocybin can produce temporary changes in perception, emotion, and sense of self, with effects typically lasting four to six hours.Common side effects may include nausea, headache, dizziness, and increased heart rate, which are generally short-lived.
In recent years, there has been growing scientific interest in psilocybin-assisted therapy as a potential treatment for conditions such as treatment-resistant depression, anxiety, and substance use disorders, and clinical trials are ongoing to better understand its safety and effectiveness.
What conditions can psilocybin help with?
Psilocybin-assisted therapy is being actively studied as a potential treatment for a range of mental health conditions, with the strongest evidence to date in depression. Multiple randomized clinical trials have shown that a single dose of psilocybin, when combined with psychological support, can produce rapid and sustained reductions in depressive symptoms in people with major depressive disorder (MDD) and treatment-resistant depression (TRD), with effects in some studies lasting three months or longer. Beyond depression, clinical research is exploring psilocybin's potential for anxiety — particularly in people facing life-threatening illnesses such as cancer — where early studies have shown meaningful and lasting reductions in both anxiety and depressive symptoms. Preliminary evidence also supports psilocybin's potential in substance use disorders, including tobacco (smoking cessation) and alcohol use disorder, as well as obsessive-compulsive disorder (OCD), where recent small trials have shown significant symptom reductions. Emerging or early-stage research is also investigating psilocybin for conditions such as eating disorders (including anorexia nervosa), cluster headaches, and depression associated with early Alzheimer's disease.
A distinctive feature of psilocybin therapy is the role of the subjective experience itself. Research consistently shows that 66% to 86% of individuals who receive psilocybin in a therapeutic setting rate the experience as among the most spiritually meaningful of their lives. These experiences — often described as mystical or transcendent — can include a profound sense of unity, interconnectedness, personal insight, and a deeper sense of meaning in life. Importantly, the intensity of these mystical-type experiences has been found to predict better therapeutic outcomes across multiple conditions, including depression, anxiety, smoking cessation, and alcohol use disorder. Studies have also shown that psilocybin use leads to a robust and lasting increase in a person's sense of "presence of meaning" in life, and that emotional breakthroughs and feelings of personal growth during sessions are associated with improvements in mental health. Researchers believe these experiences may help people break free from rigid, negative patterns of thinking and open new perspectives on themselves, their relationships, and their lives — a process sometimes called "meaning-making." While the exact mechanisms are still being studied, the therapeutic power of psilocybin appears to extend beyond its biological effects on the brain to include these deeply personal psychological and spiritual dimensions of the experience.
It is important to note that while results so far are encouraging, most studies have been small, and larger Phase III clinical trials are still underway to confirm these findings before psilocybin can be considered a standard treatment. Psilocybin therapy is always administered in a supervised clinical setting with trained professionals, and it is not appropriate for everyone — individuals with a history of psychosis, mania, or certain other conditions are typically excluded from treatment.
Is psilocybin addictive?
Based on the available scientific evidence, psilocybin is not considered addictive. Unlike substances such as alcohol, opioids, or nicotine, psilocybin does not produce compulsive drug-seeking behavior, physical dependence, or withdrawal symptoms. In animal studies, animals cannot be trained to repeatedly self-administer psilocybin — a key test used to measure a drug's addictive potential. In a comprehensive analysis of the harm potential of various substances, psilocybin received the lowest harm score of any drug evaluated (a score of 5 out of 100), compared to alcohol (72), heroin (55), and even benzodiazepines (15).
Researchers at Johns Hopkins University who formally evaluated psilocybin's abuse potential concluded that, if approved as a medicine, it would be appropriate for Schedule IV classification — the same category as medications considered to have a relatively low potential for abuse and dependence. In clinical trials, psilocybin has been found to have a minimal adverse event profile and low potential for addiction, and no participants have developed substance abuse problems following treatment.
In fact, psilocybin is actually being studied as a treatment for addiction itself, with promising early results in helping people quit smoking and reduce harmful alcohol use. While psilocybin remains a powerful substance that should only be used in supervised, clinical settings with proper screening and support, the current evidence consistently indicates that it does not carry the risk of addiction associated with many other controlled substances.
What about SSRIs, Medication Interactions, and Psilocybin Therapy?
If you are currently taking an SSRI (such as sertraline, escitalopram, or fluoxetine) or another antidepressant, you should never stop or adjust your medication on your own before a psilocybin session. The relationship between SSRIs and psilocybin is complex and still being actively studied. Research suggests that SSRIs may reduce the intensity of the psilocybin experience, and this dampening effect can persist for as long as three to six months after stopping the medication — meaning that simply discontinuing your antidepressant may not guarantee a stronger response and could put you at risk.
At the same time, a recent comprehensive review of 18 studies found that combining antidepressants with psilocybin is generally safe and tolerable, with no clearly increased risk of serotonin syndrome — particularly for psilocybin, which carries a lower risk than some other serotonergic combinations. However, every person's clinical picture is different: factors such as the specific medication you take, your dosage, how long you have been on it, the severity of your condition, and your personal mental health history all influence the risks and benefits of any medication change.
Stopping an antidepressant abruptly can lead to discontinuation syndrome (withdrawal-like symptoms), worsening depression, or increased suicidal thoughts, which is why any decision about tapering or adjusting psychotropic medications must be made in close collaboration with a trained mental health professional especially one who is psychedelically informed — such as a psychiatric mental health nurse practitioner, psychiatrist or prescribing provider — who can carefully assess your individual situation, supervise any medication changes, monitor your mental health throughout the process, and provide follow-up care. In short, this is not a decision to make alone — please work with your treatment team to develop a plan that is safe and personalized for you.
What is the process of psilocybin facilitation in ORegon?
coming soon...
Let’s Work Together
Get in touch so we can start working together.
bottom of page